scholarly journals Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy

2020 ◽  
Vol 79 (5) ◽  
pp. 465-473
Author(s):  
Kathryn Gauthreaux ◽  
Tyler A Bonnett ◽  
Lilah M Besser ◽  
Willa D Brenowitz ◽  
Merilee Teylan ◽  
...  

Abstract It remains unclear what clinical features inform the accuracy of a clinical diagnosis of Alzheimer disease (AD). Data were obtained from the National Alzheimer’s Coordinating Center to compare clinical and neuropathologic features among participants who did or did not have Alzheimer disease neuropathologic changes (ADNC) at autopsy. Participants (1854) had a clinical Alzheimer dementia diagnosis and ADNC at autopsy (Confirmed-AD), 204 participants had an AD diagnosis and no ADNC (AD-Mimics), and 253 participants had no AD diagnosis and ADNC (Unidentified-AD). Compared to Confirmed-AD participants, AD-Mimics had less severe cognitive impairment, while Unidentified-AD participants displayed more parkinsonian signs, depression, and behavioral problems. This study highlights the importance of developing a complete panel of biomarkers as a tool to inform clinical diagnoses, as clinical phenotypes that are typically associated with diseases other than AD may result in inaccurate diagnoses.

Author(s):  
Margaret Lock

This chapter looks at the adoption in the 1980s of the clinical diagnosis known as “mild cognitive impairment” (MCI). Formal recognition of MCI, the value of which continues to be debated in some circles, is the result of an exerted effort to systematically identify incipient Alzheimer disease (AD) in the clinic and is closely associated with the founding of specialist memory clinics. The chapter presents ethnographic findings of interviews with individuals who have been diagnosed with MCI. The move toward the prevention of AD represents a shift in which it is assumed that embodied risk can be made manifest in the form of biomarkers. This shift is to be accomplished by researching, standardizing, and gradually routinizing the use of several biomarkers believed to put individuals at increased risk for AD.


1996 ◽  
Vol 10 (4) ◽  
pp. 180-188 ◽  
Author(s):  
D X Rasmusson ◽  
J Brandt ◽  
C Steele ◽  
J C Hedreen ◽  
J C Troncoso ◽  
...  

2022 ◽  
Vol 8 (2) ◽  
pp. e655
Author(s):  
Alana S. Campbell ◽  
Charlotte C.G. Ho ◽  
Merve Atık ◽  
Mariet Allen ◽  
Sarah Lincoln ◽  
...  

Background and ObjectivesPutative loss-of-function (pLOF) ABCA7 variants that increase Alzheimer disease (AD) risk were identified; however, deep phenotypic characterization of these variants in mutation carriers is limited. We aimed to obtain deep clinical phenotypes of ABCA7 pLOF mutation carriers from a large retrospectively reviewed series.MethodsGenotypes were determined for 5,353 individuals evaluated at Mayo Clinic for 6 reported ABCA7 pLOF variants (p.E709fs, p.Trp1214X, p.L1403fs, c.4416+2T>G, p.E1679X, and c.5570+5G>C). Medical records of 100 mutation carriers were reviewed for demographics, clinical phenotypes, and diagnoses. Eleven mutation carriers had autopsy-based neuropathologic diagnoses.ResultsWe confirmed that ABCA7 pLOF mutations confer AD risk in our series of 2,495 participants with AD and 2,858 cognitively unaffected participants. Clinical review of 100 mutation carriers demonstrated phenotypic variability of clinical presentations with both memory and nonmemory cognitive impairment and a subset presenting with motor symptoms. There was a wide range of age at onset of cognitive symptoms (ages 56–92 years, mean = 75.6). Ten of the 11 autopsied mutation carriers had AD neuropathology. ABCA7 pLOF mutation carriers had higher rates of depression (41.6%) and first-degree relatives with cognitive impairment (38.1%) compared with the general population.DiscussionOur study provides a deep clinical review of phenotypic characteristics of mutation carriers for 6 ABCA7 pLOF mutations. Although memory impairment was the most common initial symptom, nonmemory cognitive and/or motor symptoms were present in a substantial number of mutation carriers, highlighting the heterogeneity of clinical features associated with these mutations. Likewise, although AD neuropathology is the most common, it is not the only autopsy-based diagnosis. Presence of earlier ages at onset, higher rates of depression, and first-degree relatives with cognitive impairment among mutation carriers suggest that these genetic variants may have more aggressive clinical features than AD in the general population. This deep phenotyping study of ABCA7 pLOF mutation carriers provides essential genotype-phenotype correlations for future precision medicine approaches in the clinical setting.


Neurology ◽  
2017 ◽  
Vol 88 (13) ◽  
pp. 1273-1281 ◽  
Author(s):  
Gregory S. Day ◽  
Tae Sung Lim ◽  
Jason Hassenstab ◽  
Alison M. Goate ◽  
Elizabeth A. Grant ◽  
...  

Objective:To identify clinical features that reliably differentiate individuals with cognitive impairment due to corticobasal degeneration (CBD) and Alzheimer disease (AD).Methods:Clinical features were compared between individuals with autopsy-proven CBD (n = 17) and AD (n = 16). All individuals presented with prominent cognitive complaints and were evaluated annually with semistructured interviews, detailed neurologic examinations, and neuropsychological testing.Results:Substantial overlap was observed between individuals with dementia due to CBD and AD concerning presenting complaints, median (range) duration of symptoms before assessment (CBD = 3.0 [0–5.0] years, AD = 2.5 [0–8.0] years; p = 0.96), and median (range) baseline dementia severity (Clinical Dementia Rating Sum of Boxes: CBD = 3.5 [0–12.0], AD = 4.25 [0.5–9.0], p = 0.49). Subsequent emergence of asymmetric motor/sensory signs, hyperreflexia, gait abnormalities, parkinsonism, falls, urinary incontinence, and extraocular movement abnormalities identified individuals with CBD, with ≥3 discriminating features detected in 80% of individuals within 3.1 years (95% confidence interval 2.9–3.3) of the initial assessment. Individuals with CBD exhibited accelerated worsening of illness severity and declines in episodic memory, executive functioning, and letter fluency. Semiquantitative pathologic assessment revealed prominent tau pathology within the frontal and parietal lobes of CBD cases. Comorbid AD neuropathologic change was present in 59% (10 of 17) of CBD cases but did not associate with the clinical phenotype, rate of dementia progression, or dementia duration.Conclusions:CBD may mimic AD dementia early in its disease course. Interval screening for discriminating clinical features may improve antemortem diagnosis in individuals with CBD and prominent cognitive symptoms.


Neurology ◽  
2015 ◽  
Vol 85 (10) ◽  
pp. 898-904 ◽  
Author(s):  
Kumar B. Rajan ◽  
Robert S. Wilson ◽  
Jennifer Weuve ◽  
Lisa L. Barnes ◽  
Denis A. Evans

2011 ◽  
Vol 41 (1) ◽  
pp. 71-89 ◽  
Author(s):  
Tatsuro Kondoh ◽  
Atsushi Kanno ◽  
Hiroshi Itoh ◽  
Mikiro Nakashima ◽  
Ryoko Honda ◽  
...  

Objective: Down syndrome (DS) patients share certain neuropathological features with Alzheimer disease patients. A randomized, double-blind, placebo-controlled study was performed to investigate the efficacy and safety of donepezil, an Alzheimer disease drug, for DS patients. Method: Twenty-one DS patients with severe cognitive impairment were assigned to take donepezil (3 mg daily) or a placebo for 24 weeks, and evaluated for activities in daily lives by concisely modified International Classification of Functioning, Disability and Health (ICF) scaling system. Results: ICF scores significantly increased without any adverse effects in the donepezil group in comparison to those in the placebo control. Among the individual functions tested, there was a dramatic improvement in the global mental functions and in specific mental functions. Conclusions: Donepezil may effectively and safely improve overall functioning of DS patients with severe cognitive impairment.


Author(s):  
E.M. Martin ◽  
R.S. Wilson ◽  
R.D. Penn ◽  
J.H. Fox ◽  
R.A. Clasen ◽  
...  

Abstract:This paper reports neuropsychologic and pathologic data for eleven patients with a clinical diagnosis of probable Alzheimer disease (AD) according to recently proposed NINCDS criteria. In all cases, the clinical diagnoses were verified by cortical biopsy using histopathologic criteria for definite AD. Similar tissue samples from nine non-demented autopsied patients were also evaluated and none received an histopathologic diagnosis of AD. Correlations between cortical plaque counts and neuropsychologic test scores are also presented. These data have important implications for 1) the accuracy of clinical diagnosis in AD; 2) the validity of NINCDS criteria for the clinical and pathologic diagnosis of AD; and 3) the utility of cognitive test scores as indicators of disease severity.


2019 ◽  
Vol 19 (7) ◽  
pp. 1022-1031 ◽  
Author(s):  
Paula D. Cebrián ◽  
Omar Cauli

Background: Many neurological disorders lead to institutionalization and can be accompanied in their advanced stages by functional impairment, and progressive loss of mobility, and cognitive alterations. Objective: We analyzed the relationship between functional impairment and cognitive performance and its related subdomains in individuals with Parkinson’s disease, Alzheimer’s disease accompanied by motor dysfunction, and with other neurological disorders characterized by both motor and cognitive problems. Methods: All participants lived in nursing homes (Valencia, Spain) and underwent cognitive evaluation with the Mini-Mental State Examination; functional assessment of independence in activities of daily living using the Barthel score and Katz index; and assessment of mobility with the elderly mobility scale. Results: The mean age of the subjects was 82.8 ± 0.6 years, 47% of the sample included individuals with Parkinson’s disease, and 48 % of the sample presented severe cognitive impairment. Direct significant relationships were found between the level of cognitive impairment and functional capacity (p < 0.01) and mobility (p < 0.05). Among the different domains, memory impairment was not associated with altered activities of daily living or mobility. The functional impairment and the risk of severe cognitive impairment were significantly (p<0.05) higher in female compared to male patients. Among comorbidities, overweight/obesity and diabetes were significantly (p < 0.05) associated with poor cognitive performance in those individuals with mild/moderate cognitive impairment. Conclusion: In institutionalized individuals with movement disorders there is an association between functional and cognitive impairment. Reduction of over-weight and proper control of diabetes may represent novel targets for improving cognitive function at such early stages.


Sign in / Sign up

Export Citation Format

Share Document